SUMMARY Seventy infants with suspected bacterial infection in the first 48 hours of life were treated either with piperacillin and flucloxacillin or with penicillin and gentamicin. Infection was confirmed and successfully eradicated in 6 of the 35 infants receiving piperacillin and flucloxacillin. Four infants treated with penicillin and gentamicin had confirmed infection and one deteriorated initially but then recovered when treated with piperacillin. Serum piperacillin concentrations above 100 mg/l and cerebrospinal fluid piperacillin concentrations of 2.6-6 mg/l were noted for up to four hours and 7 hours respectively, even in the absence of inflamed meninges, after administration of piperacillin 100 mg/kg body weight intravenously. Median half life of piperacillin was 6.5 hours and was prolonged in renal impairment. Piperacillin is considered to be a safe and effective first line single agent treatment for early neonatal infection but because some Escherichia coli are resistant to it we recommend that a second agent be used in critically ill infants with neutropenia or meningitis.
SUMMARY Seventy infants with suspected bacterial infection in the first 48 hours of life were treated either with piperacillin and flucloxacillin or with penicillin and gentamicin. Infection was confirmed and successfully eradicated in 6 of the 35 infants receiving piperacillin and flucloxacillin. Four infants treated with penicillin and gentamicin had confirmed infection and one deteriorated initially but then recovered when treated with piperacillin. Serum piperacillin concentrations above 100 mg/l and cerebrospinal fluid piperacillin concentrations of 2.6-6 mg/l were noted for up to four hours and 7 hours respectively, even in the absence of inflamed meninges, after administration of piperacillin 100 mg/kg body weight intravenously. Median half life of piperacillin was 6.5 hours and was prolonged in renal impairment. Piperacillin is considered to be a safe and effective first line single agent treatment for early neonatal infection but because some Escherichia coli are resistant to it we recommend that a second agent be used in critically ill infants with neutropenia or meningitis. The infants treated with piperacillin and flucloxacillin were similar to those treated with penicillin and gentamicin in birthweight (mean 1625 and 1665 g respectively), gestational age (mean 31.5 and 31.7 weeks respectively), incidence of membranes ruptured for more than 24 hours (46 % and 49 % respectively), incidence of maternal treatment with antibiotics (29% and 37 % respectively), and age at start of treatment with antibiotics (mean 12.2 and 10 *2 hours respectively).
Clinical evidence confirmed infection in 6 infants treated with piperacillin and flucloxacillin and in four treated with penicillin and gentamicin. Blood cultures were positive in one of the 6 and two out of the four respectively. Perinatal pathogens were isolated from other sites ( Piperacillin assays on serum before and after exchange transfusion and on the waste blood from the exchange showed that all the piperacillin was removed by a two volume exchange transfusion.
Discussion
Piperacillin and flucloxacillin were successful in eradicating organisms in the infants with proved early infection. Within the group treated with penicillin and gentamicin the condition of one infant with pseudomonas meningitis deteriorated and treatment had to be changed. None After the end ofthe period of study we encountered four infants with early onset Gram negative septicaemia (one with meningitis). Two of the organisms were fully sensitive to piperacillin and two were moderately resistant. Meningitis developed while the infant was being treated with penicillin and gentamicin. In critically ill infants with severe neutropenia, and in neonatal meningitis, we recommend that piperacillin be used in conjunction with a second drug such as an aminoglycoside or a third generation cephalosporin.
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